Australian Institute of Health and Welfare (2022) Diabetes: Australian facts, AIHW, Australian Government, accessed 28 November 2022.
Australian Institute of Health and Welfare. (2022). Diabetes: Australian facts. Retrieved from https://pp.aihw.gov.au/reports/diabetes/diabetes
Diabetes: Australian facts. Australian Institute of Health and Welfare, 13 July 2022, https://pp.aihw.gov.au/reports/diabetes/diabetes
Australian Institute of Health and Welfare. Diabetes: Australian facts [Internet]. Canberra: Australian Institute of Health and Welfare, 2022 [cited 2022 Nov. 28]. Available from: https://pp.aihw.gov.au/reports/diabetes/diabetes
Australian Institute of Health and Welfare (AIHW) 2022, Diabetes: Australian facts, viewed 28 November 2022, https://pp.aihw.gov.au/reports/diabetes/diabetes
Get citations as an Endnote file:
In 2020–21, there were over 16.5 million prescriptions dispensed for diabetes medicines through Section 85 of the Pharmaceutical Benefits Scheme (PBS) and Repatriation Pharmaceutical Benefits Scheme (RPBS), representing 5.3% of total prescriptions. Over one third of those claims (5.4 million) were for metformin which was the 7th highest dispensed medicine, costing over $50 million from out-of-pocket payments and government subsidies.
Diabetes medicines are key elements in preventing and treating diabetes and its risk factors. They are most commonly used to help manage blood glucose levels.
Types of diabetes medicines
People living with diabetes may require medications including insulin to help manage their blood glucose levels. All people with type 1 diabetes will require insulin. There are a variety of diabetes medicines used in Australia:
Insulin: This is a hormone made by beta cells in the pancreas. Insulin is released into the blood stream where it helps to move glucose from food that is eaten into the body’s cells to be used as energy. Injectable insulin is provided to people living with diabetes to supplement or replace insulin produced by the body to help reduce the level of glucose in the blood.
Biguanides: Also known as metformin, these are tablets which lower blood glucose levels by reducing the amount of stored glucose released by the liver, slowing the absorption of glucose from the intestine, and helping the body to become more sensitive to insulin so that its own insulin works better.
Sulphonylureas: This group of tablets lower blood glucose levels by stimulating the pancreas to release more insulin.
Thiazolidinediones: These medicines help to lower blood glucose levels by increasing the effect of the body’s own insulin, especially on muscle and fat cells.
Alpha Glucosidase Inhibitors: These help to slow down the digestion and absorption of certain dietary carbohydrates.
Dipeptidyl peptidase 4 (DPP-4) inhibitors: These inhibit the enzyme DPP-4 which enhances the levels of active incretin hormones and act to lower blood glucose levels by increasing insulin secretion and decreasing secretion of glucagon (a hormone that has the opposite effect of insulin, that is, by increasing blood glucose levels).
Glucagon-like peptide-1 receptor agonists (GLP-1a): GLP-1 is a hormone that is produced in the body when you eat which stimulates the pancreas to secrete insulin to reduce blood glucose levels. Medicines belonging to the GLP-1 receptor agonist (GLP-1a) class mimic the effects of GLP-1 to reduce blood glucose level and are normally given as an injection.
Sodium-glucose transporter (SGLT2) inhibitors: These are a class of tablet which lower plasma glucose concentrations by increasing renal excretion of glucose (Diabetes Australia 2021).
The PBS and RPBS are Australian Government programs that subsidise approved prescriptions for medicines to make them more affordable. Medicines may be discounted through this subsidy and require a co-payment from the patient to reach the gap between the subsidy and the cost of the medicines. Some medicines are subsidised enough to be under the co-payment threshold and not require any further out-of-pocket costs to the person.
Prescriptions dispensed through the PBS for diabetes medicines increased by 24% between 2017–18 and 2020–21, from 13.4 million to 16.5 million (Figure 1). The increase across this period was due to PBS subsidised prescriptions which included an out-of-pocket expense for the person.
Prescriptions dispensed for diabetes medicines made up 5.3% of the total number of prescriptions dispensed in 2020–21, an increase of 18% from 2017–18 (4.5%).
The chart shows the number of prescriptions dispensed for diabetes medicines, by co-payment status between 2017–18 and 2020–21. Over the period, diabetes medicines increased from 13.4 million to 16.5 million. The increase across this period was due to PBS subsidised prescriptions which included an out-of-pocket expense for the person.
Overall, prescriptions dispensed for thiazolidinediones and alpha glucosidase inhibitors have been decreasing over time, and there was a small decrease in the number dispensed for insulin in 2020–21. All other diabetes medicines have recorded increasing prescriptions dispensed over time. Combination therapies and other blood glucose lowering medications such as I GLP-1a recorded the largest increases from 2017–18 to 2020–21 (36% and 136%, respectively) (Figure 2).
In 2020, over 16,000 people living with type 2 diabetes-initiated insulin therapy according to the National (insulin-treated) Diabetes Register (1,800 per 100,000 population).
Insulin is a hormone made by beta cells in the pancreas. For people living with type 1 diabetes, the body does not produce insulin and daily insulin injections or infusion via an insulin pump are required to survive. Not all people living with type 2 diabetes require insulin therapy initially, but most will require some form of insulin treatment to maintain blood glucose levels over time. For people with type 2 diabetes, insulin is now considered a second-line therapy after initial treatment with metformin, depending on the clinical context, and early intervention with insulin can be beneficial for long-term outcomes in some patients (Wong and Tabet 2015).
In 2020, the incidence of insulin therapy in people living with type 2 diabetes was:
The butterfly chart shows the incidence of insulin therapy for type 2 diabetes by age group in 2020. Rates were highest in males and females aged 10–39 (4,083 and 7,738 per 100,000 population).
After controlling for the age structure of the population, the incidence of insulin therapy for people living with type 2 diabetes decreased slightly between 2000 and 2020 (down 4.4%, overall). The incidence rate was highest in 2009 (around 6,000 per 100,000 population) (Figure 4).
The line chart shows a slight decline in the incidence rate of insulin therapy for people living with type 2 diabetes between 2000 and 2020 from 4,050 to 3,870 per 100,000 population.
In 2020, the age-standardised incidence of insulin therapy for people living with type 2 diabetes:
The horizontal bar chart shows that for males and females the incidence of insulin therapy in people living with type 2 diabetes in 2020, was lower among people living in remote and very remote areas, and people living in the lowest socioeconomic areas.
Note: Incidence rates of insulin-treated type 2 diabetes for Indigenous Australians have been excluded from this report, as the NDR may underestimate the number of Aboriginal and Torres Strait Islander people with diabetes registered. For more information see the ‘Methods and classifications’ section of the Australian Institute of Health and Welfare’s Incidence of insulin-treated diabetes in Australia report.
Of all females (aged 15–49) diagnosed with gestational diabetes in 2019–20, at the time of giving birth in hospital:
In 2019–20, females who managed their gestational diabetes:
Diabetes Australia (2021) Medicine to treat diabetes, Diabetes Australia website, accessed 15 December 2021.
Wong J and Tabet E (2015) The introduction of insulin in type 2 diabetes mellitus, Australian Family Physician, 44(5):278–83, PMID: 26042399.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.